Emily Oster

8 min Read Emily Oster

Emily Oster

New RSV Prevention Drug for Babies and Toddlers

And who should consider getting it

Emily Oster

8 min Read

It’s almost September, which means cooler running weather, kids finally getting back to school, and … respiratory viruses. Respiratory viruses tend to peak in the fall and winter, when people spend more time indoors in crowded venues. Last fall was especially bad — as I talked about then, an early RSV season overlapped with croup, and a post-COVID immunity debt made everything worse.

Fingers crossed that this fall will be back to our more “normal” pre-COVID patterns, but that still means a lot of illness. The three big concerns for the fall: COVID, the flu, and RSV. There are vaccines for both COVID and the flu, but until this season, there has not been any good way to prevent RSV.

This is unfortunate, because when we consider babies and small children, RSV is the most concerning of these big three. You can read a longer explainer on RSV here, but the bottom line is that infection presents a significant risk of hospitalization for young children, especially infants born preterm or children with respiratory conditions. There are an estimated 100 to 500 deaths among children from RSV each year.

In the past year, there have been three advances in RSV prevention. The first, which I talked about here, is a vaccine for adults over 65 (the other very vulnerable group outside of babies).

The second is the recommended use of the same vaccine for pregnant people. When given later in pregnancy, it protects infants in their first six months. On Monday, the FDA approved this use of the vaccine. If you want to understand more about this option for protecting your infant, go back to the earlier post on RSV vaccines. If you’re pregnant now, it could be a great option. One note is that some concerns have been raised about higher preterm birth with the vaccine, although differences across groups were not statistically significant in the trial. The FDA has asked the companies for follow-up monitoring on this option.

The third advance, the topic for today, is the approval of a drug to prevent RSV in babies and toddlers.

Overview

Several weeks ago, the FDA approved a new drug, called Beyfortus, to prevent RSV in infants and vulnerable toddlers. You can see the full FDA press release here. The medication is a monoclonal antibody — basically, it provides protection by delivering RSV antibodies directly to the patient. This drug isn’t a vaccine, but it is delivered in a shot. The drug is approved for newborns and infants entering their first RSV season (i.e. those who were not born last fall) and for kids up to 24 months who have some risk factors (for example, those who were preterm or have had lung issues in the past).

It’s worth pausing on the reason for this particular designation. RSV is ubiquitous. The vast majority of people will get it many times in their lives, and for most older children and adults, it presents as a mild cold. The groups who are at risk for more serious illness are babies under 1, older adults, and individuals with lung conditions.

The goal of RSV prevention is to prevent RSV in these more vulnerable groups. In the case of older adults, the idea is that they will get the RSV vaccine each year, similar to how people get the flu vaccine now. For babies, the idea is to give them the RSV drug preventionin at least their first year to prevent infection during the most vulnerable period. It is likely that these children will get RSV for the first time in their second RSV season. They will not avoid it indefinitely, but they will get it for the first time when they are less likely to have serious illness.

With this background, we can frame the question. For parents of children who were born after last fall, who have not yet had RSV: Should you get them this treatment? Let’s look to the trial data.

Trial data on efficacy

The first trial of this medication was published in 2020 in the New England Journal of Medicine, based on data from the 2016-2017 RSV season. The population in the trial was infants born between 29 and 35 weeks of gestation, a group known to be at high risk for complications from RSV. The trial included 1,453 infants, of whom two-thirds were given the drug (here, under its generic name nirsevimab) and a third of whom got a placebo. As usual in this type of trial, which group people were in was hidden to the doctors and to the patients (“double blind”).

The group that got the drug had significantly less RSV. There was a 70% reduction in any RSV needing medical attention and a 78% reduction in RSV hospitalization. Four percent of the placebo group were hospitalized with RSV, versus 0.8% of the treated group.

This is a very good efficacy profile. In terms of safety, there were no notable differences in adverse events across the two groups. There were three deaths in the placebo group and two in the treated group, although none of these were thought to be related to the drug.

This first trial focused on the highest-risk preterm infants. A second trial, published in 2022, used a very similar design but recruited infants born at 35 weeks or after. Most of the infants in the trial (86%) were born at or after 37 weeks, so considered full-term. This population is lower-risk overall, but there was still strong evidence of the efficacy of the treatment.

The chance of any RSV requiring medical attention was reduced by 74%, and the chance of hospitalization was reduced by 62%. It is worth noting that this second efficacy figure is based on much smaller numbers of hospitalizations (six in one group, eight in the other), so it is not statistically precise.

In terms of safety: the overall share of infants with adverse events were similar in the two groups. There were three deaths in the treatment group and none in the placebo group, but on detailed investigation it did not appear likely that any of these deaths were related to the drug

These main trials focused on the category of “infants in their first RSV season.” A third trial, also published in a short piece in the NEJM, focused on the safety of this drug in a population of older children who were high-risk (in this case, with congenital heart disease). This trial tested nirsevimab against the existing option for high-risk infants, a drug called palivizumab that requires monthly dosing during the season. The efficacy of the drugs was similar (as expected), and the safety profile also looked similar (which was the point of the trial). Sadly, there were also six deaths in this trial — five in the treated group and one in the placebo group — but they were not thought to be related to the vaccination.

(One question you might ask: How would they know if deaths were related? The answer is that there is an extremely detailed process in these trials for following up on any adverse event, especially serious ones, to get all the possible information in order to evaluate whether it might have been related to the drug.)

The FDA conclusion from the trial data was that this is an option that shows great efficacy in preventing RSV in infants, and it appears safe as an option for medically compromised older children. This latter group already has access to the other option (palivizumab), but the newer option seems to deliver the same protection in a single dose.

What’s next?

The manufacturer of Beyfortus has indicated that it should be available ahead of this winter’s RSV season. You’re likely to hear about it from your pediatrician, either at a fall well-child visit or in direct outreach.

Like with all new medications, there will be people who are eager and excited to get this immediately, and there will be those who feel more cautious. This medication has been approved in Europe for a year already, and the trial data is compelling, but drug treatments for babies are a fraught choice for many. And this is a case, unlike some, where the value of treatment is really to the individual child. We aren’t urging people to vaccinate their babies to protect older people; it’s an urge to protect the babies themselves. Which really does make this an individual family choice.

What I will say here about the choice is that RSV is dangerous for a lot of babies, and the efficacy numbers on this drug are extremely good. If you have an infant — especially one born preterm — going into this first RSV season, I would urge you to get them this shot.

Note: This piece was updated at 8:55 AM on 8/24 to correct the error in referring to this new drug as a vaccine. We regret the error.

0 Comments
Inline Feedbacks
View all comments
A Black pregnant woman rests her hands on her stomach while waiting for a doctor's appointment.

3 min read

The Facts About RSV

Over the past months I’ve talked about RSV in passing a number of times. Specifically: I talk about it in Read more

Emily Oster
A blue box of tissue on a light blue background.

Nov 18 2022

2 min read

What Is the Contagion Window for RSV?

My 18-month-old tested positive for RSV on Sunday. We are supposed to travel this weekend to see family for the Read more

Emily Oster
A doctor placed a bandaid on the arm of a pregnant person after administering a vaccination.

May 30 2023

8 min read

RSV and Vaccines

Respiratory syncytial virus, or RSV, is a common respiratory virus. Unless you are very, very unusual, by the time you’re Read more

Emily Oster
A parent holds and infant while a doctor listens to their lungs.

Dec 19 2023

2 min read

Are Babies Who Are Hospitalized for RSV at Increased Risk for Other Illnesses?

My two-month-old (born at 36 weeks) was in the ICU for 11 days with RSV last month. Is he more Read more

Emily Oster

Instagram

left right
Milestones. We celebrate them in pregnancy, in parenting, and they’re a fun thing to celebrate at work too. Just a couple years ago I couldn’t have foreseen what this community would grow into. Today, there are over 400,000 of you here—asking questions, making others feel seen wherever they may be in their journey, and sharing information that supports data > panic. 

It has been a busy summer for the team at ParentData. I’d love to take a moment here to celebrate the 400k milestone. As I’ve said before, it’s more important than ever to put good data in the hands of parents. 

Share this post with a friend who could use a little more data, and a little less parenting overwhelm. 

📷 Me and my oldest, collaborating on “Expecting Better”

Milestones. We celebrate them in pregnancy, in parenting, and they’re a fun thing to celebrate at work too. Just a couple years ago I couldn’t have foreseen what this community would grow into. Today, there are over 400,000 of you here—asking questions, making others feel seen wherever they may be in their journey, and sharing information that supports data > panic.

It has been a busy summer for the team at ParentData. I’d love to take a moment here to celebrate the 400k milestone. As I’ve said before, it’s more important than ever to put good data in the hands of parents.

Share this post with a friend who could use a little more data, and a little less parenting overwhelm.

📷 Me and my oldest, collaborating on “Expecting Better”
...

I spend a lot of time talking people down after they read the latest panic headline. In most cases, these articles create an unnecessary amount of stress around pregnancy and parenting. This is my pro tip for understanding whether the risk presented is something you should really be worrying about.

Comment “link” for an article with other tools to help you navigate risk and uncertainty.

#emilyoster #parentdata #riskmanagement #parentstruggles #parentingstruggles

I spend a lot of time talking people down after they read the latest panic headline. In most cases, these articles create an unnecessary amount of stress around pregnancy and parenting. This is my pro tip for understanding whether the risk presented is something you should really be worrying about.

Comment “link” for an article with other tools to help you navigate risk and uncertainty.

#emilyoster #parentdata #riskmanagement #parentstruggles #parentingstruggles
...

Here’s why I think you don’t have to throw away your baby bottles.

Here’s why I think you don’t have to throw away your baby bottles. ...

Drop your toddlers favorite thing right now in the comments—then grab some popcorn.

Original thread source: Reddit @croc_docs

Drop your toddlers favorite thing right now in the comments—then grab some popcorn.

Original thread source: Reddit @croc_docs
...

Just keep wiping.

Just keep wiping. ...

Dr. Gillian Goddard sums up what she learned from the Hot Flash  S e x  Survey! Here are some key data takeaways:

🌶️ Among respondents, the most common s e x u a l frequency was 1 to 2 times per month, followed closely by 1 to 2 times per week
🌶️ 37% have found their sweet spot and are happy with the frequency of s e x they are having
🌶️ About 64% of respondents were very or somewhat satisfied with the quality of the s e x they are having

Do any of these findings surprise you? Let us know in the comments!

#hotflash #intimacy #midlifepleasure #parentdata #relationships

Dr. Gillian Goddard sums up what she learned from the Hot Flash S e x Survey! Here are some key data takeaways:

🌶️ Among respondents, the most common s e x u a l frequency was 1 to 2 times per month, followed closely by 1 to 2 times per week
🌶️ 37% have found their sweet spot and are happy with the frequency of s e x they are having
🌶️ About 64% of respondents were very or somewhat satisfied with the quality of the s e x they are having

Do any of these findings surprise you? Let us know in the comments!

#hotflash #intimacy #midlifepleasure #parentdata #relationships
...

Should your kid be in a car seat on the plane? The AAP recommends that you put kids under 40 pounds into a car seat on airplanes. However, airlines don’t require car seats.

Here’s what we know from a data standpoint:
✈️ The risk of injury to a child on a plane without a carseat is very small (about 1 in 250,000)
✈️ A JAMA Pediatrics paper estimates about 0.4 child air crash deaths per year might be prevented in the U.S. with car seats 
✈️ Cars are far more dangerous than airplanes! The same JAMA paper suggests that if 5% to 10% of families switched to driving, then we would expect more total deaths as a result of this policy. 

If you want to buy a seat for your lap infant, or bring a car seat for an older child, by all means do so! But the additional protection based on the numbers is extremely small.

#parentdata #emilyoster #flyingwithkids #flyingwithbaby #carseats #carseatsafety

Should your kid be in a car seat on the plane? The AAP recommends that you put kids under 40 pounds into a car seat on airplanes. However, airlines don’t require car seats.

Here’s what we know from a data standpoint:
✈️ The risk of injury to a child on a plane without a carseat is very small (about 1 in 250,000)
✈️ A JAMA Pediatrics paper estimates about 0.4 child air crash deaths per year might be prevented in the U.S. with car seats
✈️ Cars are far more dangerous than airplanes! The same JAMA paper suggests that if 5% to 10% of families switched to driving, then we would expect more total deaths as a result of this policy.

If you want to buy a seat for your lap infant, or bring a car seat for an older child, by all means do so! But the additional protection based on the numbers is extremely small.

#parentdata #emilyoster #flyingwithkids #flyingwithbaby #carseats #carseatsafety
...

SLEEP DATA 💤 PART 2: Let’s talk about naps. Comment “Link” for an article on what we learned about daytime sleep!

The first three months of life are a chaotic combination of irregular napping, many naps, and a few brave or lucky souls who appear to have already arrived at a two-to-three nap schedule. Over the next few months, the naps consolidate to three and then to two. By the 10-to-12-month period, a very large share of kids are napping a consistent two naps per day. Over the period between 12 and 18 months, this shifts toward one nap. And then sometime in the range of 3 to 5 years, naps are dropped. What I think is perhaps most useful about this graph is it gives a lot of color to the average napping ages that we often hear. 

Note: Survey data came from the ParentData audience and users of the Nanit sleep monitor system. Both audiences skew higher-education and higher-income than the average, and mostly have younger children. The final sample is 14,919 children. For more insights on our respondents, read the full article.

SLEEP DATA 💤 PART 2: Let’s talk about naps. Comment “Link” for an article on what we learned about daytime sleep!

The first three months of life are a chaotic combination of irregular napping, many naps, and a few brave or lucky souls who appear to have already arrived at a two-to-three nap schedule. Over the next few months, the naps consolidate to three and then to two. By the 10-to-12-month period, a very large share of kids are napping a consistent two naps per day. Over the period between 12 and 18 months, this shifts toward one nap. And then sometime in the range of 3 to 5 years, naps are dropped. What I think is perhaps most useful about this graph is it gives a lot of color to the average napping ages that we often hear.

Note: Survey data came from the ParentData audience and users of the Nanit sleep monitor system. Both audiences skew higher-education and higher-income than the average, and mostly have younger children. The final sample is 14,919 children. For more insights on our respondents, read the full article.
...

Happy Father’s Day to the Fathers and Father figures in our ParentData community! 

Tag a Dad who this holiday may be tricky for. We’re sending you love. 💛

Happy Father’s Day to the Fathers and Father figures in our ParentData community!

Tag a Dad who this holiday may be tricky for. We’re sending you love. 💛
...

“Whilst googling things like ‘new dad sad’ and ‘why am I crying new dad,’ I came across an article written by a doctor who had trouble connecting with his second child. I read the symptoms and felt an odd sense of relief.” Today we’re bringing back an essay by Kevin Maguire of @newfatherhood about his experience with paternal postpartum depression. We need to demystify these issues in order to change things for the better. Comment “Link” for a DM to read his full essay.

#parentdata #postpartum #postpartumdepression #paternalmentalhealth #newparents #emilyoster

“Whilst googling things like ‘new dad sad’ and ‘why am I crying new dad,’ I came across an article written by a doctor who had trouble connecting with his second child. I read the symptoms and felt an odd sense of relief.” Today we’re bringing back an essay by Kevin Maguire of @newfatherhood about his experience with paternal postpartum depression. We need to demystify these issues in order to change things for the better. Comment “Link” for a DM to read his full essay.

#parentdata #postpartum #postpartumdepression #paternalmentalhealth #newparents #emilyoster
...

What does the data say about children who look more like one parent? Do they also inherit more character traits and mannerisms from that parent? Let’s talk about it 🔎

#emilyoster #parentdata #parentingcommunity #lookslikedaddy #lookslikemommy

What does the data say about children who look more like one parent? Do they also inherit more character traits and mannerisms from that parent? Let’s talk about it 🔎

#emilyoster #parentdata #parentingcommunity #lookslikedaddy #lookslikemommy
...

SLEEP DATA 💤 We asked you all about your kids’ sleep—and got nearly 15,000 survey responses to better understand kids’ sleep patterns. Comment “Link” for an article that breaks down our findings!

This graph shows sleeping location by age. You’ll notice that for the first three months, most kids are in their own sleeping location in a parent’s room. Then, over the first year, this switches toward their own room. As kids age, sharing a room with a sibling becomes more common. 

Head to the newsletter for more and stay tuned for part two next week on naps! 🌙

#parentdata #emilyoster #childsleep #babysleep #parentingcommunity

SLEEP DATA 💤 We asked you all about your kids’ sleep—and got nearly 15,000 survey responses to better understand kids’ sleep patterns. Comment “Link” for an article that breaks down our findings!

This graph shows sleeping location by age. You’ll notice that for the first three months, most kids are in their own sleeping location in a parent’s room. Then, over the first year, this switches toward their own room. As kids age, sharing a room with a sibling becomes more common.

Head to the newsletter for more and stay tuned for part two next week on naps! 🌙

#parentdata #emilyoster #childsleep #babysleep #parentingcommunity
...

Weekends are good for extra cups of ☕️ and listening to podcasts. I asked our team how they pod—most people said on walks or during chores. What about you?

Comment “Link” to subscribe to ParentData with Emily Oster, joined by some excellent guests.

#parentdata #parentdatapodcast #parentingpodcast #parentingtips #emilyoster

Weekends are good for extra cups of ☕️ and listening to podcasts. I asked our team how they pod—most people said on walks or during chores. What about you?

Comment “Link” to subscribe to ParentData with Emily Oster, joined by some excellent guests.

#parentdata #parentdatapodcast #parentingpodcast #parentingtips #emilyoster
...

Humility. That’s why. That’s the whole reason.

#emilyoster #secondbaby #parentingjokes #parentinghumor

Humility. That’s why. That’s the whole reason.

#emilyoster #secondbaby #parentingjokes #parentinghumor
...

Bug season is upon us. Besides annoyance, this can bring up safety concerns, particularly with ticks. They are carriers of diseases, most notably Lyme disease. So what’s the best course of action?

Prevention is key! I suggest:
⭐ Regular tick checks
⭐ Using bug sprays with DEET 
⭐ Wearing long sleeves and pants in the woods

Some parents worry about DEET, but repellants with up to 30% DEET are recommended by both the CDC and AAP. The data says you’re in the clear, so go for it. Enjoy your summer!

#parentdata #emilyoster #tickseason #bugbites #bugspray

Bug season is upon us. Besides annoyance, this can bring up safety concerns, particularly with ticks. They are carriers of diseases, most notably Lyme disease. So what’s the best course of action?

Prevention is key! I suggest:
⭐ Regular tick checks
⭐ Using bug sprays with DEET
⭐ Wearing long sleeves and pants in the woods

Some parents worry about DEET, but repellants with up to 30% DEET are recommended by both the CDC and AAP. The data says you’re in the clear, so go for it. Enjoy your summer!

#parentdata #emilyoster #tickseason #bugbites #bugspray
...